Manidipino Viatris

Manidipine, the active ingredient in Manidipino Viatris, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Manidipino Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is a calcium channel blocker used to manage high blood pressure.

Hypertension: lowers elevated arterial pressure and helps reduce the risk of cardiovascular complications.

Manidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or throat. - Myocardial infarction: rare heart attack events. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, consider the following safety measures.

Monitor blood pressure: ensure adequate control and avoid excessive drops. Assess hepatic function: adjust use if liver impairment is present. Evaluate for heart failure: use cautiously in patients with reduced cardiac output. Use with caution in the elderly: increased sensitivity to hypotensive effects. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. Store at room temperature: keep in the original container, protect from moisture.

Manidipine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Concomitant antihypertensives (e.g., ACE inhibitors, other calcium blockers): risk of additive hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance blood‑pressure lowering effect. - Beta‑blockers: monitor for bradycardia or excessive BP reduction. - NSAIDs: may attenuate antihypertensive response. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Lithium: monitor serum levels due to possible increase.